Prescription for pharma profits: Go big

The pharma M&A scene is heating up. Pfizer has reportedly made a second offer to purchase British pharmaceuticals giant AstraZeneca in a deal valued at just under $100 billion. If the deal goes through, it would be the largest purchase ever of a U.K. company.

"We've seen three types of deals occurring: A growth type of deal for new products, a strategy type of deal like Novartis and Glaxo and a synergy type of deal like Valeant and Allergan, where a company can cut costs and drive revenue," said John Eade, Argus Research president on CNBC's "Fast Money."

He explained that while mid-cap companies are more affordable, large cap companies that offer cost-cutting benefits on the regulatory and marketing sides are very alluring.

"I think Bristol-Myers, it's the biggest of my three picks. It's an $80 billion company. It's more of a cost-savings deal. Bristol-Myers operating margins are about half of what we see others in the industry make," added Eade.

Contact Fast Money

  • Showtimes

    Halftime Report - Weekdays 12p ET
    Fast Money - Weekdays 5p ET

Halftime Report

  • Bill Nygren, Oakmark Fund, explains why Apache, Bank of America and Google will be winners in 2015.

  • Nick Tiller, Sustainable America founder and chairman, tells CNBC's Kate Kelly oil prices are poised for a tradable rally. Tiller likes the Brent ETF and energy sector.

  • Discussing interesting trends contributing to the market's rally into year's end, with the FMHR trader Josh Brown and Dan Greenhaus, BTIG.